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Fibrous dysplasia (FD) is a genetic, noninheritable rare bone disease caused by a postzygotic activating mutation of the α subunit
of the stimulatory G-protein causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no
cure has been identified for FD/McCune–Albright syndrome (MAS) and treatment is symptomatic and aimed at decreasing pain
and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including
bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysio-
logical issues and explore novel pharmacological targets for the management of FD/MAS.
In this article, we review literature on the medical treatment of FD/MAS, discuss the unresolved pathophysiological issues and
explore novel pharmacological targets for the management of FD/MAS.
Introduction
Fibrous dysplasia/McCune–Albright syndrome (FD/MAS) is
a genetic, noninheritable rare bone disease caused by a
postzygotic activating mutation of the α subunit of the
stimulatory G-protein (Gsα) [1]. In the skeleton, this results
in the overproduction of cAMP in affected cells of the oste-
ogenic lineage, leading to the accelerated production of
bone marrow stromal cells (BMSC), while inhibiting the dif-
ferentiation of these progenitor cells into mature osteoblasts
[2]. Despite expressing early osteoblast markers such as alka-
line phosphatase (ALP), these immature cells are dysfunc-
tional, leading to the laying down of fibro-osseous tissue
that is under-mineralized, of poor quality and of disturbed
micro-architecture. In extensive disease, the mineralization
defect is further exacerbated by increased fibroblast growth
factor 23 (FGF-23) expression by the mass of osteogenic
mutated cells leading to renal phosphate wasting and
impaired 1.25 vitamin D production [3]. The disturbed bone
microarchitecture and mineralization defect decrease bone
strength, resulting in increased risk for deformities and frac-
tures [4] (Figure 1).
A further pathophysiological characteristic of FD lesions
is the increased number of osteoclasts present in and around
FD lesions, leading to a local increase in bone resorption [5].
The local increase in osteoclastogenesis is believed to be due
to the significant up-regulation of the receptor activator of
nuclear factor κ-B ligand (RANKL) by GNAS-mutated osteo-
genic cells [2, 6] and increased production of interleukin-6
(IL-6) by these cells [7]. The observed focal increase in num-
ber and clustering of osteoclasts exhibits a tunneling resorp-
tion pattern and endosteal fibrosis analogous to changes
characteristically observed in hyperparathyroidism [8]. It
has been suggested that local increase in bone turnover
would be associated with increased deposition of abnormal,
under-mineralized fibro-osseous tissue, leading to pain,
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further expansion of FD lesions and increased risk for defor-
mities and fractures.
It has also been suggested that the local increase in oste-
oclastogenesis may be further promoted by increased PTHrP
expression, amplifying the effects of mutated osteogenic
cells to upregulate RANK-L and down-regulate OPG [9]. In-
creased bone resorption leads to increased abnormal bone
formation by the mutated immature osteoblasts, perpetuat-
ing the vicious circle that leads to continuing formation of
abnormal bone, lesion expansion, pain, and increasing risk
for deformities and fractures (Figure 1). The somatic mosai-
cism associated with the postzygotic nature of the GNAS mu-
tation results in a wide spectrum of clinical manifestations,
ranging from the completely asymptomatic, to the severely
invalidated patient with multiple skeletal lesions, sometimes
in combination with hyperfunctioning endocrinopathies as
seen in the context of MAS [1].
Pitfalls and challenges in the
pharmacological management of FD
There is no cure for FD/MAS, and to date there is no approved
pharmacological treatment for the disorder’s ubiquitous
manifestations. Pain in particular remains a significant chal-
lenge for the treating physician. Pain at the site of FD lesions
may occur as a result of a complete fracture, an impending
fracture or microfractures, due to mineralization defects or
abnormal mechanical forces in case of deformities. Pain
may also be related to extent, severity or activity, although
it has been suggested that there may be no correlation be-
tween skeletal pain and total disease burden as seen in pa-
tients with bone metastases [10–12]. This suggests that bone
remodelling and disease burden may not be the only contrib-
utors to bone pain, and that an additional factor such as neu-
ropathic involvement may also play a role [13, 14]. It has thus
been proposed that analogous to the pain associated with
bone tumours, pain arising from FD lesions may also be in-
duced or exacerbated by sensory nerve involvement and/or
the formation of neuromas in or around these lesions [10].
Traditionally, the main therapeutic approach to the man-
agement of FD/MAS is a surgical one, ranging from curettage
of FD lesions in the early 60s [15], to customized blade plates
more recently [16]. The notion of using pharmacological
agents in the management of FD/MAS has evolved in the
70s, based on the accumulation of evidence for increased
bone resorption in FD lesions. This has opened the way for
the use of antiresorptive agents in FD/MAS, aiming at de-
creasing the local increase in bone turnover, in the
Figure 1
Pathophysiology of fibrous dysplasia. FGF-23, fibroblast growth factor-23; BMSC, bone marrow stromal cells
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management of FD thereby potentially decreasing or
preventing expansion of lesions, controlling symptoms and
decreasing the risk for deformities and fractures. A number
of antiresorptive drugs have been used off label, of which
the most frequently prescribed have been the
bisphosphonates, followed more recently by the anti-RANK
ligand antibody denosumab [17].
An essential first step before considering the use of
any antiresorptive agent, however, is the identification
and treatment of FGF23-mediated hypophosphataemia,
potentially leading to increased pain, deformity and in-
creased fracture risk [18–22]. Treatment of FGF23-mediated
hypophosphataemia requires the use of active vitamin D
metabolites or analogues due to the inhibitory effects of in-
creased levels of FGF23 on the renal α-hydroxylase enzyme
resulting in low circulating levels of 1,25-dihydoxy vitamin
D, as also observed in X-linked hypophosphataemic rickets
[23]. Additional phosphate supplementation may be
required, particularly in children in whom sufficient
phosphate levels are essential for normal growth and the
maintenance of bone quality. Attention should also been
given to the presence of vitamin D deficiency or
insufficiency, which should also be corrected before
starting treatment with antiresorptive agents.
A second important step to be taken before initiating
treatment with antiresorptive agents is the identification
and treatment of potentially associated endocrinopathies, es-
pecially in the more severe forms of FD/MAS. This is espe-
cially the case for GH-excess, in which the stimulatory
effects of excess of growth hormone on bone turnover may
compete or negate the inhibitory effects of antiresorptive
treatment, calling for higher doses of bisphosphonates. Thy-
roid abnormalities are not uncommon in patients with
FD/MAS, including T3 thyrotoxicosis due to a shifted
T3/T4 ratio suggesting an increase in intrathyroidal conver-
sion of T4 into the active metabolite T3, nearly always in
the presence of echographic structural changes in the thy-
roid gland. Thyroid pathology should be identified and
treated as required as potentially also increasing FD mor-
bidity [24, 25].
The unravelling of further aspects of the pathophysiol-
ogy of FD/MAS has led to exploring potential new pharma-
cological avenues (Figure 2), although the lack of adequate
translational tools such as appropriate animal models to
Figure 2
Current and future targets in the treatment of fibrous dysplasia. FGF-23, fibroblast growth factor-23; anti-NGF, anti-nerve growth factor; BMSC,
bone marrow stromal cells
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test new agents represents the main challenge for the
development of novel therapies in the management of
FD/MAS [2, 6].
Antiresorptives
The purpose of using antiresorptives in FD/MAS would be to
revert the local abnormality in bone turnover, decrease or
prevent the deposition of abnormal, under-mineralized
fibro-osseous tissue and associated lesion expansion, and
thereby to control the clinical manifestations of the disorder.
The first publication on the use of an antiresorptive agent
in the pharmacological management of FD/MAS appeared in
1970 and described the beneficial effects of using calcitonin
in a patient with polyostotic FD [26]. Experience with the
use of this agent in the management of FD/MAS is very scarce
and limited to a few case reports and small case series, with
mixed outcomes [26–28]. More than 50 years after its discov-
ery, the choice of calcitonin as antiresorptive has been
completely superseded by that of bisphosphonates. The use
of calcitonin is therefore not recommended in FD/MAS.
Bisphosphonates
Themost commonantiresorptivedrugs used in thepharmaco-
logical management of FD/MAS are the nitrogen-containing
bisphosphonates, which exert their antiresorptive effect by
inhibiting the mevalonate pathway by preventing post-
translational prenylation of GTP-binding proteins, resulting
in osteoclast apoptosis [29]. All published studies on the use
of bisphosphonates have been observational open studies, ex-
cept fora single randomizedcontrolled trialwith theuseoforal
alendronate [30].
In the early 1990s in a small case series of nine adult pa-
tients with FD/MAS was the first to demonstrate the benefi-
cial effect of intravenously administered pamidronate (APD)
at a dose of 60mg daily for 3 consecutive days, every 6months
for 18 months on the clinical manifestations of FD/MAS [31].
All patients reported a decrease in pain and none of the pa-
tients developed new fractures during treatment or over
follow-up which ranged from 18–48 months. Serum alkaline
phosphatase and urinary hydroxyproline normalized on
treatment in all patients, and filling and cortical thickening
of FD lesions were observed on plain radiology in four pa-
tients. Side-effects included transient diffuse bone pain in
two patients, transient fever in three patients and symptom-
atic hypocalcaemia in two patients.
Since then, a number of publications reported variable
beneficial effects of different bisphosphonates on pain, bone
turnover markers and radiological features of FD/MAS lesions
largely in adults and children with polyostotic FD/MAS.
These publications include 18 case reports [32–49], 20 obser-
vational case series [11, 30, 31, 50–66] and a single random-
ized controlled study (RCT) using oral alendronate [30].
Case reports were predominantly on women (11/18),
seven on children and six reporting the effects of treatment
with zoledronate and pamidronate in patients with isolated
craniofacial FD (CFD) [33, 35–37, 40, 44]. Positive outcome
of treatment in the form of decreased pain was reported in
all patients, associated by a concomitant normalization in
bone turnover markers in six of the 17 patients in whom
these markers were measured before and after treatment
[37, 38, 41, 44, 47, 48]. A total of 462 patients were in-
cluded in the 20 published case series. Six of these case se-
ries included MAS patients, and one study included 106
patients with sinonasal CFD largely as part of polyostotic
FD/MAS [55]. In these case series, indication of treatment
with bisphosphonates was based on pain, (n = 13/20),
[31, 50, 51, 54–59, 61, 64, 65], increased bone turnover
markers (BTMs), (n = 9/20), [11, 30, 52, 53, 60, 62, 63, 66, 67],
or a combination of both (n = 8/20). Several publications
have reported a decrease in bone pain associated with a de-
crease in bone turnover with the use of intravenous
pamidronate [52, 53, 59, 68]. Symptoms of pain were not al-
ways a prerequisite for starting treatment with a bisphos-
phonate, in some studies this was based on the presence
of increased bone turnover markers. Notwithstanding, the
only two studies evaluating pain did not demonstrate it to
be affected beneficially by bisphosphonates: the RCT using
alendronate in children and adults with polyostotic
FD/MAS compared to placebo [30] and the open study using
bisphosphonates (type not reported) in patients with cra-
niofacial disease as part of polyostotic FD/MAS [55].
The most commonly used bisphosphonate in the
management of FD/MAS in both adults and children is
intravenous pamidronate [57, 59, 60, 64, 66]. Other
bisphosphonates have also been used, such as intravenous
zoledronate [45], intravenous and oral olpadronate [69], oral
alendronate [30], and oral risedronate [70]. The sequential
use of different bisphosphonates [50, 61, 65] and their
long-term use resulting in high cumulative doses have also
been reported [11]. Only one RCT using oral alendronate or
placebo in adults and children has been published [30]. In
this study, alendronate was administered in daily oral doses
ranging from 10 to 40 mg daily based on body weight
(40 mg daily for subjects >50 kg, 20 mg for 30–50 kg,
10 mg for 20–30 kg) in 6-month cycles for 2 years. Treatment
with this oral bisphosphonate led to a reduction in the bone
resorption marker urinary NTx-telopeptide, and to improve-
ment in areal BMD in normal bone at the lumbar spine and
in predetermined regions of FD, but had no significant effect
on the bone formation marker serum osteocalcin, on func-
tional parameters nor on pain at the end of 2 years of treat-
ment. This observed difference between bone resorption
and formation may hypothetically represent an important
factor in the failure of the agent.
The bulk of evidence for an effect of bisphosphonates on
pain in FD/MAS is derived from results of observational
studies conducted over the past 3 decades, which report var-
iable improvement in pain after initiation of treatment with
an intravenously administered bisphosphonate. These stud-
ies are lacking a control arm and the use of validated tools
in the evaluation of pain, andmay thus have been influenced
by the placebo effect. Therefore, more weight should be given
to RCTs, which are very scarce in FD/MAS. The only pub-
lished RCT showed no significant effect on pain of an oral
agent [30]. Data from the Profidys study (NCT00445575),
the only other European multicentre RCT evaluating the
efficacy of bisphosphonates in FD, which also used an oral
bisphosphonate: risedronate at a dose of 30 mg daily for
2 months every 6 months, for 1 year in symptomatic patients
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and 3 years in adult asymptomatic patients, are eagerly
awaited.
Notwithstanding, conclusions derived from RCTs on the
efficacy on pain of a bisphosphonate agent compared to
placebo can only be applied to the bisphosphonate used,
its mode of administration and the dose used in the partic-
ular RCT. Caution should be exerted in extrapolating the
findings to other bisphosphonates with a different mode
of administration or total dose used. While awaiting the re-
sults of the Profidys study, we would not currently recom-
mend the use of oral bisphosphonates in children or
adults with FD/MAS.
There are no RCT data to date on the efficacy of intrave-
nous bisphosphonates compared to placebo to reduce
FD/MAS-related pain and, to our knowledge, there are no
plans to conduct such a study in the near future. However,
based on data from observational studies [11, 71, 72], the con-
sensus recommendation is to consider a trial of short-term
treatment with intravenous bisphosphonates in the manage-
ment of FD-related pain.
Effect of bisphosphonates on bone turnover markers. In adults,
studies using bisphosphonates in FD/MAS in which BTMs
were assessed report a decrease in the various bone markers
used within few weeks of initiating treatment; however, in
children, this decrease was not observed [60]. However as in
the case of evaluating the effect of bisphosphonates on
pain, one of the main limitations of evaluating the effect of
a bisphosphonate on BTMs is that various BTMs have been
measured at various time-points of treatment, and various
bisphosphonates at various doses and schedules have been
used so that it remains very difficult to compare outcome of
studies. The relationship between increased bone turnover
markers and pain and concomitant changes in both
following treatment with a bisphosphonate has not been
systematically examined in all studies, so that no firm
conclusion can be drawn on this aspect of efficacy of
bisphosphonates.
Effect of bisphosphonates on radiological features. Several
publications demonstrate beneficial radiological changes,
potentially associated with improved bone quality and
decreased risk of complications [31, 52, 53, 56–58, 65].
Beneficial changes in radiological features have thus
included cortical thickening of FD lesions as observed after
2–6 years of follow up in three of 11 children with MAS
treated with pamidronate [57]; a decrease in the size of a
monostotic FD lesion observed on computed tomography in
three out of six patients treated with pamidronate [58]; or
progressive filling of osteolytic lesions in 54% of 58 adult
patients with MFD (n = 22) and PFD (n = 36) treated with
pamidronate [53]. Data on changes in radiological features
are, however, scarce as these have not been consistently
reported in most of the published studies. Of importance
when interpreting studies on radiographic changes in
skeletal FD lesions, is that longitudinal changes observed
may be due, at least in part, to the natural history of the
disease, particularly as burn-out of FD lesions has been
described with increasing age [72].
The most common side-effects observed with the use
of a bisphosphonate in FD/MAS have been an acute
phase reaction including transient fever after infusion
[31, 50, 52, 53, 58, 63], followed by transient bone pain
[31, 56, 63, 65] and transient hypocalcaemia [31, 50, 52,
53, 63]. Concerns about the effects of bisphosphonates
on linear growth in children has not been substantiated
also in children with FD/MAS treated with bisphosphonates
[11, 73]. There have been scarce reports of the recently
identified rare risks of osteonecrosis of the jaw (ONJ) and
atypical femoral fractures in bisphosphonate-treated
FD/MAS patients, despite their prolonged use at high cu-
mulative doses in some cases [11, 53]. It is of note that
ONJ has been reported in four FD patients, three of whom
had craniofacial FD lesions located at the site of the devel-
oping ONJ and the fourth had documented poor dental
health before starting treatment [74].
Based on the above literature findings and our Centre’s
long-standing experience on efficacy and safety of treatment
of patients with FD/MAS with bisphosphonates, we do advo-
cate the use of intravenous bisphosphonates in these pa-
tients, although we have so far only done so in patients
with measurable increases in BTMs, with or without associ-
ated pain symptoms. However, other centres do treat patients
with bisphosphonates primarily to decrease pain, regardless
of bone turnover. Some patients however, particularly those
with high skeletal burden scores, initial growth hormone ex-
cess and high FGF-23 levels, all reflecting extensive and se-
vere disease, may be refractory to treatment with these
agents [44, 65], which calls for alternative approaches for
their management.
The anti-RANKL antibody denosumab. The human skeletal
progenitor cells expressing the mutated Gsα protein have
been shown to produce excess receptor activator of nuclear
factor κ-b ligand (RANKL) [6]. The documented increased
expression of RANKL by cells of the osteogenic lineage in
FD lesions provided the rationale for exploring the use of
the anti-RANKL denosumab as a therapeutic option in the
pharmacological treatment of FD/MAS. Using this agent
was also supported by in vitro studies showing that BMSCs,
transfected with the specific R201-C or -H mutation and
exposed to an anti-RANKL antibody, demonstrated a
decrease in cAMP expression. RANKL plays an essential
role in osteoclastogenesis by binding to its receptor on the
membrane of osteoclast progenitors. The binding of
RANKL to RANK induces osteoclast differentiation,
activation and survival, leading to increased bone
resorption. However, the observed effect of denosumab on
GSα mutated BMSCs suggests that in FD/MAS, RANKL
inhibition may have an additional direct effect on BMSCs,
independently of the established role of anti-RANKL to
inhibit osteoclastogenesis. The creation of GsαR201C-
transgenic mice that develop an FD skeletal phenotype has
made it possible to explore anti-RANKL as a therapeutic
option in the management of FD [6]. A decrease in the size
of osteolytic FD lesions, fewer deformities and fewer FD
lesions were reported in abstract form in mice treated with
an anti-RANKL antibody compared to nontreated controls
[73]. In treated mice, discontinuation of treatment was
associated with histological evidence of rebound of the
disease. There was no radiographic difference observed at
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3 months between anti-RANKL treated mice and nontreated
control mice [73, 75].
Denosumab, a humanized anti-RANKL antibody, has
been approved for the treatment of osteoporosis and skeletal
tumour metastases, and has been shown to induce tumour re-
duction and bone formation in patients with giant cell tu-
mours of bone [76, 77]. Over the past 6 years, five case
reports have been published on the effect of denosumab in
patients with FD [17, 78–81]. A decrease of pain was reported
in all patients, and BTMs normalized within a few hours [79]
to 3 weeks [78] in all five cases.
In 2012, Boyce and colleagues reported on a 9-year-old
boy with MAS and an FD lesion in the femur, which was
rapidly expanding despite pamidronate treatment causing
pain and functional impairment [17]. Denosumab was initi-
ated at a dose of 1 mg kg–1 monthly, increasing stepwise ev-
ery 3 months to 1.25, 1.5 and 1.75 mg kg–1. Tumour growth
had slowed down from 4.2% to 0.56% per month after
9 months of treatment, and BTMs normalized already after
the first dose, remaining suppressed thereafter for the dura-
tion of treatment. However, the patient had become
hypophosphataemic and hypocalcaemic and had developed
secondary hyperparathyroidism soon after the first injection
so that he needed supplementation with phosphorus,
calcitriol andcalcium[17].Denosumabtreatmentwas stopped
before his seventh dose as he had sustained a femoral fracture
at the site of an FD lesion after falling out of bed. Within
2 months of discontinuing treatment with denosumab, the
child developed severe symptomatic hypercalcaemia requir-
ing treatment with high dose bisphosphonates: pamidronate
followed by zoledronate to normalize. Similar to the case with
the use of bisphosphonates in children, sclerotic bands were
observed in the radius and ulna of the child, parallel to the
growth plates, reflecting periods of inhibition of resorption
followed by periods of normal bone formation at the time
intervals of administration, rather than a persistent suppres-
sion of skeletal activity.
A rapid positive outcome of denosumab treatment has
been reported by others [78–81], also using the dosage of
60 mg administered subcutaneously at 3–9 months intervals.
Both pain and BTMs are reported to respond quite rapidly
following each dose, although the beneficial effect on bone
pain seems to wane within weeks to a maximum of 4 months
after a dose. In all case reports, patients were switched to
denosumab because of insufficient effect of bisphosphonate
therapy on pain and/or BTMs.
A case series from our Centre, published as an abstract,
demonstrates a positive outcome of treatment with
denosumab in 12 adult patients with polyostotic FD/MAS
with persistent pain and persistently increased bone turnover
markers despite long-term treatment with bisphosphonates
[82]. Bone turnover markers normalized in all patients after
initiation of denosumab therapy, and all reported an im-
provement in pain symptoms.
Although these early findings with the use of denosumab
in FD/MAS appear to be promising, especially in the manage-
ment of patients with severe skeletal burden who are refrac-
tory to treatment with bisphosphonates, there are a number
of safety issues that remain to be addressed before this potent
antiresorptive agent could be advocated for use in all patients
with FD/MAS. One of these questions clearly relate to the
rebound effect observed after inadvertently discontinuing
treatment. This question is in the process of being formally
addressed in a study about to start at the National Institutes
of Health, NCT03571191. In this study, patients will receive
a monthly dose of denosumab 120 mg for 6 consecutive
months, including a loading dose on days 7 and 14 of the first
month. The primary outcome of this study will be the change
in BTMs, with secondary endpoints pain, lesion intensity and
effect of discontinuation of therapy as patients will be
followed for 21 months. In addition to safety, the second
question to be addressed is the evidence for the efficacy of
this drug as obtained by means of a multicentre RCT includ-
ing sufficient numbers of patients, which is currently being
designed by the International FD/MAS Consortium. Until
data from these two studies become available, caution should
be exerted with the indiscriminate use of this potent
antiresorptive agent in FD/MAS.
Over the past decade, there has been increasing aware-
ness about the potential risks associated with the long-term
use of antiresorptive agents, such as ONJ. Better knowledge
about these risks and measures to be adopted to prevent
them (such as securing adequate dental hygiene, identifying
and treating vitamin D deficiency and FGF23-mediated
hypophosphatemia and FD/MAS-associated hyperactive
endocrinopathies, particularly GH-excess) before initiating
treatment with antiresorptives should be extended to all
health care professionals involved in the management of
patients with FD/MAS.
Other therapeutic options
Other than the antiresorptives, there have only been a hand-
ful of potential therapeutic options in the pharmacological
management of FD/MAS, all largely based on increasing in-
sight into the pathophysiology of the disorder.
Anti-IL6 (tocilizumab)
IL-6 is one of several cytokines implicated in stimulating
bone resorption [83]. IL-6 expression is upregulated by PTH
and acts via Gsα and the cAMP-mediated signalling pathway
[84]. It has been hypothesized that since cAMP is a known
stimulant of IL-6 gene activity [85], increased cAMP produc-
tion (as seen in FD/MAS) could lead to IL-6 overexpression,
a proposedmechanism of FD related bone pain [5, 10]. To test
this hypothesis in vitro, increased IL-6 secretion was induced
by transfecting MC3T3 cells with Gsα, reproducing the same
activating mutation as seen in FD/MAS [86]. Cells isolated
from FD lesions were found to secrete higher levels of IL-6
[87]. FD lesions with a high number of osteoclasts showed
the presence of a direct link between GNAS mutations in
BMSCs and IL-6 production, but also defined the complex
role of IL-6 in regulating osteoclastogenesis in FD in vivo [7].
Patterns of osteoclastogenesis and bone resorption do not
only reflect the cell-autonomous effects of GNAS mutations
in osteogenic cells (including IL-6 production), but also the
local and systemic context to which non-osteogenic cells, lo-
cal proportions of wild-type vs. mutated cells, and systemic
hormones contribute. In addition, it was observed that IL-6
knockout mice were protected from bone loss [7]. Combining
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these findings, de Boysson and colleagues [88] hypothesized
that Il-6 inhibition might lead to reduction of bone pain in
FD/MAS and went on to treat a 35-year-old woman with
severe CFD and persisting headaches, with a score of 4–5/10
despite bisphosphonate treatment, with the anti-IL-6
antibody tocilizumab at a dose of 600 mg monthly, with a
complete disappearance of pain after the second month of
treatment. Treatment was continued at the lower dose of
400 mg two-monthly for a further 6 months after which it
was discontinued. There were no adverse effects associated
with the treatment or its discontinuation [89]. At this
point, one single trial is registered (NCT1791842) using
tocilizumab in patients with FD/MAS related pain resistant
to bisphosphonates; however, the status of this study is cur-
rently unknown.
The identification of potential novel treatment
targets
Despite the significant advances in understanding the patho-
physiology of the skeletal and extra skeletal manifestations of
FD/MAS, a number of molecular and cellular consequences of
a GNAS mutation remain unresolved. This is largely due to
the difficulties encountered by the mosaicism of the disease
and this hampers the development of mouse models, which
would mimic the full clinical picture of the FD/MAS human
disease. Several models have been developed; however, none
have been able to fully capture all the characteristics of the
human disease. Specific models mimicking the skeletal dis-
ease or the extraskeletal manifestations came to development
[75, 90] allowing the possibility to not only evaluate the anti-
RANKL antibody denosumab, but also the speculation on
new therapies. Zhao and colleagues [2] recently developed a
conditional tetracycline-inducible animal model expressing
the Gsα mutation (R201C) in the skeletal stem cells. Here,
typical FD bone lesions develop in both embryos and adult
mice in <2 weeks following doxycycline administration [2].
The mutation resulted in the increased expression of RANKL
by mutated osteogenic cells leading to the typical FD-related
histomorphometric changes. Gsα expression ablation by
doxycycline withdrawal resulted in FD-like lesion regres-
sion, supporting the rationale for Gsα-targeted drugs to pur-
sue curation. Such a model, which develops FD-like lesions
that can form rapidly and revert on cessation of mutant
Gsα expression, may provide a breakthrough in expanding
the possibilities for medical treatment for FD/MAS such as
gene therapy using suramin sodium (SS), that can inhibit
Gsα activation [91]. Using a knock-out mouse model in
which the human FD R201H mutation was conditionally
knocked into the corresponding mouse GNAS locus, Khan
and colleagues [90] found upregulated Wnt/β-catenin sig-
nalling in the FD mutant mouse which exhibited human
FD features. They also showed significant rescue of the FD
phenotype by removing one lipoprotein receptor-related
protein (LRP)-6 copy [90]. These findings open new avenues
in the management of FD/MAS by showing that Wnt/β-
catenin signalling may represent an interesting new target
for drug development in Gsα activation bone disorders.
Although this is an exciting development, much more work
is required in this field before gene therapy is considered in
the clinical management of FD/MAS.
Anti-FGF23
Patients with severe polyostotic disease are likely to have
high FGF-23 levels due to high mutated osteogenic cell
disease burden often associated with renal phosphate
wasting [3]. High levels of FGF-23 are also associated with
inhibition of the one-α hydroxylase enzyme and a decrease
in 1.25-dihydroxy vitamin D levels (Figure 1). The abnor-
malities in mineral metabolism can be readily reverted
by treatment with active vitamin D metabolites and phos-
phate supplements; however, especially during growth,
high doses might be needed, which can lead to complica-
tions such as nephrocalcinosis, renal stones and tertiary
hyperparathyroidism. The use of a human monoclonal anti-
body to FGF-23 is another option that was shown to be
effective in X-linked hypophosphataemic rickets, in which
a mutation in the PHEX gene leads to high FGF-23 levels,
renal phosphate wasting and hypophosphataemia. The hu-
man monoclonal antibody to FGF-23 binds to and directly
inhibits the activity of FGF-23, thereby increasing renal
tubular reabsorption of phosphate, increasing circulating
levels of 1.25-OH2 levels and improving clinical out-
come [92]. However, the number of secreting mutated osteo-
genic cells due to a high skeletal burden of the disease is not
affected and the use of anti-FGF-23 would only be beneficial
in case of untreatable symptomatic hypophosphataemia
despite optimal active vitamin D metabolites and phosphate
supplementation. There are currently no literature data on
outcome of treatment of FD/MAS with anti-FGF-23.
Anti-nerve growth fact
Nerve growth factor (NGF) was discovered as a tumour tissue-
produced soluble factor that promotes growth and differenti-
ation of sensory and sympathetic ganglia [93]. NGF plays a
significant role in the generation of pain and hyperalgesia
in acute and chronic pain in rodents [94]. Injury and inflam-
mation increase NGF expression, since activated macro-
phages express NGF and are thus able to directly sensitize
primary afferent neurons expressing NGF receptors. Since
the discovery of NGF, a number of studies have been con-
ducted in models of bone metastasis to address the potential
use of NGF-modifying drugs in reducing cancer-related pain.
Administration of a blocking antibody to NGF in a rodent
model for prostate metastasis has thus been shown to result
in a significant reduction in pain [95]. There is as yet no evi-
dence for a contributory role for NGF in the pathophysiology
of pain in FD/MAS and no data available in animal models of
FD/MAS to suggest a beneficial effect of their use in control-
ling pain. However, more translational work addressing the
mechanism of pain in FD/MAS and its potential management
is certainly warranted in view of the severe and sometimes
crippling pain, which may be very difficult to control that
not only can affect patients with the most severe forms of
FD/MAS, but also sometimes those with monostotic disease.
The past 3 decades since the discovery of the mutation re-
sponsible for the manifestations of FD/MAS have witnessed
significant advances in the understanding of the pathophys-
iology of the skeletal and extraskeletal manifestations of this
ubiquitous disorder. Whereas bisphosphonates remain to
date the cornerstone of the medical treatment of symptom-
atic patients with FD/MAS, opinion is still divided on which
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bisphosphonate to use, at which dose and at which dosing
interval. Most commonly used schedules are pamidronate at
a dose of 90 mg 3-monthly or 180 mg 6-monthly in adults,
and 1 mg kg–1 with a maximum of 30 mg per day for 3
consecutive days in children. Denosumab is emerging as a
useful alternative in patients refractory to treatment with
bisphosphonates, but caution should be exerted with their
use because of concern about a deleterious rebound effect
on discontinuation of treatment. There is a clearly unmet
need for multicentre RCTs including sufficient patients to
confirm the efficacy and safety of currently used drugs in con-
trolling pain and decreasing the risk of expansion of FD le-
sions, and thereby the risk of deformities and fractures.
Further translational studies are warranted to address unre-
solved pathophysiology issues and explore novel pharmaco-
logical targets for the management of FD/MAS.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY [96], and are
permanently archived in the Concise Guide to PHARMA-
COLOGY 2017/18 [97].
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